Merck today announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/merck-licenses-crispr-gene-editing-technology-to-evotec-5868